ERBB2 and breast cancer: Prognostic model for BM from BC patients were reported and there is biologic evidence for higher propensity for BM in HER2-positive and TNBC patients (Ahn et al. 2012; Heitz et al. 2009; Sperduto et al. 2012), although routine screening of BM for high risk patients did not show definite survival benefit (Niwinska et al. 2007).While general therapeutic nihilism should be avoided, it is still important to recognize that the number of BM, the extent of the systemic disease, and also the BC subtype have to be taken into account when choosing individual treatment regimens.